Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS

被引：0
|
作者：
Lipton, R. B. [1 ]
Chalermpalanupap, N. [2 ]
Tatsuoka, Y. [3 ]
Nagy, K. [4 ]
Liu, Y. [5 ]
Carr, K. [5 ]
McAllister, P. [6 ]
Nahas, S. J. [7 ]
Trugman, J. M. [2 ]
Sacco, S. [8 ]
机构：
[1] Albert Einstein Coll Med, Bronx, MA USA
[2] AbbVie, Madison, NJ USA
[3] Tatsuoka Neurol Clin, Kyoto, Japan
[4] AbbVie, Budapest, Hungary
[5] AbbVie, N Chicago, IL USA
[6] New England Inst Neurol & Headache, Stamford, CT USA
[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[8] Univ Aquila, Laquila, Italy
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P036
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Response Rates With Oral Atogepant in Participants With Prior Preventive Treatment Failure: Results From ELEVATE
    Pozo-Rosich, Patricia
    Nagy, Krisztian
    Tassorelli, Cristina
    Lanteri-Minet, Michel
    Sacco, Sara
    Nezadal, Tomas
    Finnegan, Michelle
    Luo, Lei
    Gandhi, Pranav
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (1supp) : 31 - 32
  • [32] Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine and Documented Prior Inadequate Response to 2-4 Classes of Migraine Preventive Medications
    Naegel, S.
    Cohen, J. M.
    Campos, V. Ramirez
    Barash, S.
    Ning, X.
    Kudrow, D.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 170 - 170
  • [33] Efficacy of Fremanezumab by Prior Number of Preventive Treatments With Inadequate Response in Patients With Episodic Migraine and Chronic Migraine: Results of the International, Multicenter Phase 3b
    Pazdera, L.
    Cohen, J. M.
    Ning, X.
    Ramirez-Campos, V
    Yang, R.
    HEADACHE, 2020, 60 : 13 - 14
  • [34] Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Lipton, R.
    Ashina, M.
    Tassorelli, C.
    Martin, V.
    Yu, S. Y.
    Nagy, K.
    Schwefel, B.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [35] Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine and Documented Prior Inadequate Response to 2-4 Classes of Migraine Preventive Medications
    Nagel, S.
    Cohen, J. M.
    Campos, V. Ramirez
    Barash, S.
    Ning, X.
    Kudrow, D.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 114 - 114
  • [36] Early Onset of Efficacy With Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Ailani, Jessica
    Reuter, Uwe
    Graboski, Corrie
    Klein, Brad C.
    Yu, Sung Y.
    Nagy, Krisztian
    Guo, Hua
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 32 - 33
  • [37] Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Lipton, Richard B.
    Ashina, Messoud
    Tassorelli, Cristina
    Martin, Vincent
    Yu, Sung Y.
    Nagy, Krisztian
    Schwefel, Brittany
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 31 - 32
  • [38] Reversion from chronic to episodic migraine and clinically meaningful responses to fremanezumab in patients with inadequate response to 2-4 classes of migraine preventive medications
    Ashina, M.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Ramirez-Campos, V.
    Yang, R.
    Ailani, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [39] Annual indirect cost savings in patients with episodic or chronic migraine: Post-hoc analyses from multiple galcanezumab clinical trials
    Ford, J. H.
    Tockhorn-Heidenreich, A.
    Nichols, R. M.
    Ye, W.
    Bhandari, R.
    Tobin, J. A.
    Lipton, R. B.
    HEADACHE, 2021, 61 : 54 - 55
  • [40] Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials
    Tobin, Joshua
    Ford, Janet H.
    Tockhorn-Heidenreich, Antje
    Nichols, Russell M.
    Ye, Wenyu
    Bhandari, Rohit
    Mi, Xiaojuan
    Sharma, Karan
    Lipton, Richard B.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 630 - 639
12345